title: [Protein scaffolds as alternatives to whole antibodies: from discovery research to clinical development].
abstract: Recent advances in combinatorial protein engineering have made it possible to develop non-Ig protein scaffolds that can potentially substitute for most whole antibody-associated properties. These protein scaffolds display most of the binding properties associated with the variable domain of antibodies. In theory, many different natural human protein backbones are suitable to be used as recombinant templates for engineering ; in practice however, only a few have yielded the necessary properties to be translated into << druggable biologicals >>. Amongst these properties, potential broad specificities towards any kind of target, ease of production, small size, good tolerability and low immunogenicity are essential. Intellectual property is another key issue. In this review, a particular emphasis will be given to the most validated non-Ig scaffolds that have reached the clinical development phase.
authors.forename: Thierry
authors.initials: T
authors.lastname: Wurch
authors.forename: Peter
authors.initials: P
authors.lastname: Lowe
authors.forename: Alain
authors.initials: A
authors.lastname: Beck
authors.forename: Nathalie
authors.initials: N
authors.lastname: Corvaia
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000627:therapeutic use; D000906:Antibodies; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D001704:Biopolymers; D002986:Clinical Trials as Topic; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D005353:Fibronectins / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D051379:Mice; D008819:Mice, Nude; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010446:Peptide Fragments / Q000737:chemistry* / Q000627:therapeutic use; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use; D011487:Protein Conformation; D015202:Protein Engineering; D017434:Protein Structure, Tertiary; D011973:Receptors, LDL / Q000737:chemistry / Q000627:therapeutic use; D013205:Staphylococcal Protein A / Q000737:chemistry / Q000627:therapeutic use; D013329:Structure-Activity Relationship
chemical_list: C549680:ABY-025; C549679:AMG-220; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000906:Antibodies; D000970:Antineoplastic Agents; D001704:Biopolymers; C549678:CT-322; D005353:Fibronectins; D010446:Peptide Fragments; D010455:Peptides; D011973:Receptors, LDL; D013205:Staphylococcal Protein A; C511194:ecallantide